About Photys Therapeutics
Photys Therapeutics is a company based in Cambridge (United States) founded in 2021.. Photys Therapeutics has raised $75 million across 1 funding round from investors including Lilly, Turmeric Acquisition Corp and Mass General Brigham Ventures. Photys Therapeutics offers products and services including PROTAC, tPRIME, and PHICS. Photys Therapeutics operates in a competitive market with competitors including Accutar Biotechnology, Plexium, Lycia Therapeutics, Vicinitas and Uvic Steratics, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$75 M (USD)
in 1 rounds
-
Latest Funding Round
$75 M (USD), Series A
Sep 08, 2022
-
Investors
Lilly
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Photys Therapeutics
Photys Therapeutics offers a comprehensive portfolio of products and services, including PROTAC, tPRIME, and PHICS. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Bifunctional molecule that degrades target proteins via ubiquitination
Enhances target protein expression through proximity induction
Induces phosphorylation on specific proteins for modulation
Unlock access to complete
Funding Insights of Photys Therapeutics
Photys Therapeutics has successfully raised a total of $75M through 1 strategic funding round. The most recent funding activity was a Series A round of $75 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $75.0M
-
First Round
First Round
(08 Sep 2022)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Series A - Photys Therapeutics | Valuation | MPM Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Photys Therapeutics
Photys Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Turmeric Acquisition Corp and Mass General Brigham Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Founded Year | Domain | Location | |
|
Venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Photys Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Photys Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Photys Therapeutics Comparisons
Competitors of Photys Therapeutics
Photys Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accutar Biotechnology, Plexium, Lycia Therapeutics, Vicinitas and Uvic Steratics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-assisted tools for drug discovery are developed.
|
|
| domain | founded_year | HQ Location |
Integrated chemistry service provider
|
|
| domain | founded_year | HQ Location |
Protein degradation drugs are developed for cancer and autoimmune diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for cancer and genetic disorders
|
|
| domain | founded_year | HQ Location |
Anti-cancer drugs are developed via Proteolysis Targeting Chimera technology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Photys Therapeutics
Frequently Asked Questions about Photys Therapeutics
When was Photys Therapeutics founded?
Photys Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Photys Therapeutics located?
Photys Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Photys Therapeutics?
David Steinberg is the current CEO of Photys Therapeutics.
Is Photys Therapeutics a funded company?
Photys Therapeutics is a funded company, having raised a total of $75M across 1 funding round to date. The company's 1st funding round was a Series A of $75M, raised on Sep 08, 2022.
What does Photys Therapeutics do?
Photys Therapeutics was founded in 2021 and is based in Cambridge, United States. Operations center on biotechnology, where a proprietary bifunctional small molecules platform is utilized to regulate protein post-translational modifications. This approach aims to restore protein function, repair signaling pathways, and enhance endogenous mechanisms against diseases. A pipeline focused on oncology indications is being advanced through these efforts.
Who are the top competitors of Photys Therapeutics?
Photys Therapeutics's top competitors include Plexium, Uvic Steratics and Accutar Biotechnology.
What products or services does Photys Therapeutics offer?
Photys Therapeutics offers PROTAC, tPRIME, and PHICS.
Who are Photys Therapeutics's investors?
Photys Therapeutics has 10 investors. Key investors include Lilly, Turmeric Acquisition Corp, Mass General Brigham Ventures, Longwood Fund, and Omega Funds.